EP Patent

EP4577243A1 — Stable lipid or lipidoid nanoparticle suspensions

Assigned to Ethris GmbH · Expires 2025-07-02 · 1y expired

What this patent protects

Provided are stabilized lipid nanoparticle (LNP)/lipidoid nanoparticle (LiNP) formulations and LNP/LiNP suspensions, uses thereof and uses in method of treatment based on the findings that the addition of the surfactant to the formulations or suspensions avoids aggregation, allow…

USPTO Abstract

Provided are stabilized lipid nanoparticle (LNP)/lipidoid nanoparticle (LiNP) formulations and LNP/LiNP suspensions, uses thereof and uses in method of treatment based on the findings that the addition of the surfactant to the formulations or suspensions avoids aggregation, allowing a surprisingly long shelf life and extended stability to shaking. Said reduction of aggregation according to the invention results in a reduction of side effects of the formulations and suspension of the invention, specifically a reduction of side effects caused by vaccines formulations and anticancer formulations comprising LNPs and/or LiNPs.

Drugs covered by this patent

Patent Metadata

Patent number
EP4577243A1
Jurisdiction
EP
Classification
—
Expires
2025-07-02
Drug substance claim
No
Drug product claim
No
Assignee
Ethris GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.